{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:25:34Z","timestamp":1790526334040,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1038\/s41375-019-0463-3","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T16:08:04Z","timestamp":1554221284000},"page":"2442-2453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages"],"prefix":"10.1038","volume":"33","author":[{"given":"Antonin","family":"Papin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Tessoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Bellanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Le Bris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Maisonneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Amiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Pellat-Deceunynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"key":"463_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","volume":"125","author":"E Campo","year":"2015","unstructured":"Campo E, Rule S. Mantle cell lymphoma: evolving management strategies. Blood. 2015;125:48\u201355.","journal-title":"Blood"},{"key":"463_CR2","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1172\/JCI61272","volume":"122","author":"P Jares","year":"2012","unstructured":"Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122:3416\u201323.","journal-title":"J Clin Invest"},{"key":"463_CR3","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1182\/blood.V87.11.4483.bloodjournal87114483","volume":"87","author":"DD Weisenburger","year":"1996","unstructured":"Weisenburger DD, Armitage JO. Mantle cell lymphoma\u2014an entity comes of age. Blood. 1996;87:4483\u201394.","journal-title":"Blood"},{"key":"463_CR4","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"463_CR5","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1182\/blood-2017-10-764373","volume":"131","author":"XS Puente","year":"2018","unstructured":"Puente XS, Jares P, Campo E. Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. Blood. 2018;131:2283\u201396.","journal-title":"Blood"},{"key":"463_CR6","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","volume":"126","author":"MH Delfau-Larue","year":"2015","unstructured":"Delfau-Larue M-H, Klapper W, Berger F, Jardin F, Briere J, Salles G, et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015;126:604\u201311.","journal-title":"Blood"},{"key":"463_CR7","doi-asserted-by":"publisher","first-page":"18250","DOI":"10.1073\/pnas.1314608110","volume":"110","author":"S Be\u00e0","year":"2013","unstructured":"Be\u00e0 S, Vald\u00e9s-Mas R, Navarro A, Salaverria I, Mart\u00edn-Garcia D, Jares P, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci USA. 2013;110:18250\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"463_CR8","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.ccell.2016.09.014","volume":"30","author":"AC Queir\u00f3s","year":"2016","unstructured":"Queir\u00f3s AC, Beekman R, Vilarrasa-Blasi R, Duran-Ferrer M, Clot G, Merkel A, et al. Decoding the DNA methylome of mantle cell lymphoma in the light of the entire B cell lineage. Cancer Cell. 2016;30:806\u201321.","journal-title":"Cancer Cell"},{"key":"463_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semcancer.2013.08.011","volume":"24","author":"JA Burger","year":"2014","unstructured":"Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol. 2014;24:71\u201381.","journal-title":"Semin Cancer Biol"},{"key":"463_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.semcancer.2013.08.001","volume":"24","author":"P Am\u00e9-Thomas","year":"2014","unstructured":"Am\u00e9-Thomas P, Tarte K. The yin and the yang of follicular lymphoma cell niches: role of microenvironment heterogeneity and plasticity. Semin Cancer Biol. 2014;24:23\u201332.","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"463_CR11","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1080\/10428194.2017.1357177","volume":"59","author":"Antonin Papin","year":"2017","unstructured":"Papin A, Le Gouill S, Chiron D. Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment. Leuk Lymphoma. 2017;59:1064\u201372.","journal-title":"Leukemia & Lymphoma"},{"key":"463_CR12","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","volume":"128","author":"D Chiron","year":"2016","unstructured":"Chiron D, Bellanger C, Papin A, Tessoulin B, Dousset C, Maiga S. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood. 2016;128:2808\u201318.","journal-title":"Blood"},{"key":"463_CR13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","volume":"128","author":"NS Saba","year":"2016","unstructured":"Saba NS, Liu D, Herman SEM, Underbayev C, Tian X, Behrend D, et al. Pathogenic role of B-cell receptor signaling and canonical NF-\u03baB activation in mantle cell lymphoma. Blood. 2016;128:82\u201392.","journal-title":"Blood"},{"key":"463_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1158\/1078-0432.CCR-15-0987","volume":"22","author":"Z Chen","year":"2016","unstructured":"Chen Z, Teo AE, McCarty N. ROS-induced CXCR4 signaling regulates mantle cell lymphoma (MCL) cell survival and drug resistance in the bone marrow microenvironment via autophagy. Clin Cancer Res. 2016;22:187\u201399.","journal-title":"Clin Cancer Res"},{"key":"463_CR15","doi-asserted-by":"publisher","first-page":"8750","DOI":"10.18632\/oncotarget.3275","volume":"6","author":"D Chiron","year":"2015","unstructured":"Chiron D, Dousset C, Brosseau C, Touzeau C, Ma\u00efga S, Moreau P, et al. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Oncotarget. 2015;6:8750\u20139.","journal-title":"Oncotarget"},{"key":"463_CR16","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1182\/blood-2008-10-185827","volume":"113","author":"AV Kurtova","year":"2009","unstructured":"Kurtova AV, Tamayo AT, Ford RJ, Burger JA. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 2009;113:4604\u201313.","journal-title":"Blood"},{"key":"463_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49\u201361.","journal-title":"Immunity"},{"key":"463_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"BZ Qian","year":"2010","unstructured":"Qian B-Z, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39\u201351.","journal-title":"Cell"},{"key":"463_CR19","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma. N Engl J Med. 2010;362:875\u201385.","journal-title":"N Engl J Med"},{"key":"463_CR20","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1182\/blood-2015-04-640912","volume":"126","author":"R Amin","year":"2015","unstructured":"Amin R, Mourcin F, Uhel F, Pangault C, Ruminy P, Dupr\u00e9 L, et al. DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma. Blood. 2015;126:1911\u201320.","journal-title":"Blood"},{"key":"463_CR21","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.ccell.2016.09.007","volume":"30","author":"PH Nguyen","year":"2016","unstructured":"Nguyen P-H, Fedorchenko O, Rosen N, Koch M, Barthel R, Winarski T, et al. LYN kinase in the tumor microenvironment is essential for the progression of chronic lymphocytic leukemia. Cancer Cell. 2016;30:610\u201322.","journal-title":"Cancer Cell"},{"key":"463_CR22","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.celrep.2016.01.042","volume":"14","author":"G Galletti","year":"2016","unstructured":"Galletti G, Scielzo C, Barbaglio F, Rodriguez TV, Riba M, Lazarevic D, et al. Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression. Cell Rep. 2016;14:1748\u201360.","journal-title":"Cell Rep"},{"key":"463_CR23","doi-asserted-by":"publisher","first-page":"7254","DOI":"10.1158\/0008-5472.CAN-13-0750","volume":"73","author":"K Song","year":"2013","unstructured":"Song K, Herzog BH, Sheng M, Fu J, McDaniel JM, Chen H, et al. Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma. Cancer Res. 2013;73:7254\u201364.","journal-title":"Cancer Res"},{"key":"463_CR24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3109\/10428194.2014.901511","volume":"56","author":"LV Pham","year":"2015","unstructured":"Pham LV, Vang MT, Tamayo AT, Lu G, Challagundla P, Jorgensen JL, et al. Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease. Leuk Lymphoma. 2015;56:186\u201393.","journal-title":"Leuk Lymphoma"},{"key":"463_CR25","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1186\/s12885-016-2844-6","volume":"16","author":"M Hanf","year":"2016","unstructured":"Hanf M, Chiron D, de Visme S, Touzeau C, Maisonneuve H, Jardel H, et al. The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma. BMC Cancer [Internet]. 2016;16:802. \n                    https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5064959\/","journal-title":"BMC Cancer [Internet]"},{"key":"463_CR26","doi-asserted-by":"publisher","first-page":"e0119751","DOI":"10.1371\/journal.pone.0119751","volume":"10","author":"E Derlindati","year":"2015","unstructured":"Derlindati E, Dei Cas A, Montanini B, Spigoni V, Curella V, Aldigeri R, et al. Transcriptomic analysis of human polarized macrophages: more than one role of alternative activation? PLoS One. 2015;10:e0119751.","journal-title":"PLoS One"},{"key":"463_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","volume":"41","author":"PJ Murray","year":"2014","unstructured":"Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41:14\u201320.","journal-title":"Immunity"},{"key":"463_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/cyto.a.22643","volume":"87","author":"S Ma\u00efga","year":"2015","unstructured":"Ma\u00efga S, Brosseau C, Descamps G, Dousset C, Gomez-Bougie P, Chiron D, et al. A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines. Cytometry A. 2015;87:285\u20138.","journal-title":"Cytometry A"},{"key":"463_CR29","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"463_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/bioinformatics\/btg405","volume":"20","author":"L Gautier","year":"2004","unstructured":"Gautier L, Cope L, Bolstad BM, Irizarry RA. affy\u2014analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20:307\u201315.","journal-title":"Bioinformatics"},{"key":"463_CR31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453\u20137.","journal-title":"Nat Methods"},{"key":"463_CR32","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3324\/haematol.2010.031567","volume":"96","author":"D Vishwamitra","year":"2011","unstructured":"Vishwamitra D, Shi P, Wilson D, Manshouri R, Vega F, Schlette EJ, et al. Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma. Haematologica. 2011;96:871\u201380.","journal-title":"Haematologica"},{"key":"463_CR33","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3324\/haematol.2009.019745","volume":"95","author":"F Baran-Marszak","year":"2010","unstructured":"Baran-Marszak F, Boukhiar M, Harel S, Laguillier C, Roger C, Gressin R, et al. Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica. 2010;95:1865\u201372.","journal-title":"Haematologica"},{"key":"463_CR34","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1182\/blood-2012-04-424630","volume":"120","author":"L Zhang","year":"2012","unstructured":"Zhang L, Yang J, Qian J, Li H, Romaguera JE, Kwak LW, et al. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 2012;120:3783\u201392.","journal-title":"Blood"},{"key":"463_CR35","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1002\/jcp.26429","volume":"233","author":"A Shapouri-Moghaddam","year":"2018","unstructured":"Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili S-A, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233:6425\u201340.","journal-title":"J Cell Physiol"},{"key":"463_CR36","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399\u2013416.","journal-title":"Nat Rev Clin Oncol"},{"key":"463_CR37","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1158\/1078-0432.CCR-17-1007","volume":"23","author":"YM Yeh","year":"2017","unstructured":"Yeh Y-M, Hsu S-J, Lin P-C, Hsu K-F, Wu P-Y, Su W-C, et al. The c.1085A>G genetic variant of CSF1R gene regulates tumor immunity by altering the proliferation, polarization, and function of macrophages. Clin Cancer Res. 2017;23:6021\u201330.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"463_CR38","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1182\/blood-2018-03-838946","volume":"133","author":"David K. Edwards","year":"2018","unstructured":"Edwards DK, Watanabe-Smith K, Rofelty A, Damnernsawad A, Laderas T, Lamble A, et al. CSF1R inhibitors exhibit anti-tumor activity in acute myeloid leukemia by blocking paracrine signals from support cells. Blood. 2018;133:588\u201399","journal-title":"Blood"},{"key":"463_CR39","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1002\/ijc.29326","volume":"136","author":"S Bernard","year":"2015","unstructured":"Bernard S, Danglade D, Gardano L, Laguillier C, Lazarian G, Roger C, et al. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. Int J Cancer. 2015;136:2761\u201374.","journal-title":"Int J Cancer"},{"key":"463_CR40","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","volume":"122","author":"BY Chang","year":"2013","unstructured":"Chang BY, Francesco M, De Rooij MFM, Magadala P, Steggerda SM, Huang MM, et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 2013;122:2412\u201324.","journal-title":"Blood"},{"key":"463_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nm.3435","volume":"20","author":"R Rahal","year":"2014","unstructured":"Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, et al. Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014;20:87\u201392.","journal-title":"Nat Med"},{"key":"463_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14920","volume":"8","author":"X Zhao","year":"2017","unstructured":"Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017;8:14920.","journal-title":"Nat Commun"},{"key":"463_CR43","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.it.2011.12.001","volume":"33","author":"B Ruffell","year":"2012","unstructured":"Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 2012;33:119\u201326.","journal-title":"Trends Immunol"},{"key":"463_CR44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/nrd.2016.231","volume":"16","author":"JA Hamilton","year":"2016","unstructured":"Hamilton JA, Cook AD, Tak PP. Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases. Nat Rev Drug Discov. 2016;16:53\u201370.","journal-title":"Nat Rev Drug Discov"},{"key":"463_CR45","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","volume":"25","author":"CH Ries","year":"2014","unstructured":"Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25:846\u201359.","journal-title":"Cancer Cell"},{"key":"463_CR46","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1200\/JCO.2007.15.6521","volume":"26","author":"XD Zhu","year":"2008","unstructured":"Zhu X-D, Zhang J-B, Zhuang P-Y, Zhu H-G, Zhang W, Xiong Y-Q, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008;26:2707\u201316.","journal-title":"J Clin Oncol"},{"key":"463_CR47","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1158\/1078-0432.CCR-15-3099","volume":"22","author":"A Polk","year":"2016","unstructured":"Polk A, Lu Y, Wang T, Seymour E, Bailey NG, Singer JW, et al. Colony-stimulating factor-1 receptor is required for nurse-like cell survival in chronic lymphocytic leukemia. Clin Cancer Res. 2016;22:6118\u201328.","journal-title":"Clin Cancer Res"},{"key":"463_CR48","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19:1264\u201372.","journal-title":"Nat Med"},{"key":"463_CR49","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1182\/blood-2016-01-695395","volume":"128","author":"A Guti\u00e9rrez-Gonz\u00e1lez","year":"2016","unstructured":"Guti\u00e9rrez-Gonz\u00e1lez A, Mart\u00ednez-Moreno M, Samaniego R, Arellano-S\u00e1nchez N, Salinas-Mu\u00f1oz L, Relloso M, et al. Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma. Blood. 2016;128:2241\u201352.","journal-title":"Blood"},{"key":"463_CR50","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.1158\/0008-5472.CAN-14-3373","volume":"75","author":"DL Moughon","year":"2015","unstructured":"Moughon DL, He H, Schokrpur S, Jiang ZK, Yaqoob M, David J, et al. Macrophage blockade using CSF1R inhibitors reverses the vascular leakage underlying malignant ascites in late-stage epithelial ovarian cancer. Cancer Res. 2015;75:4742\u201352.","journal-title":"Cancer Res"},{"key":"463_CR51","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1182\/blood-2009-08-237412","volume":"115","author":"SJ Priceman","year":"2010","unstructured":"Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood. 2010;115:1461\u201371.","journal-title":"Blood"},{"key":"463_CR52","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1182\/blood-2017-10-811752","volume":"131","author":"JG Chen","year":"2018","unstructured":"Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, et al. BTKCys481Ser drives ibrutinib resistance via ERK1\/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. Blood. 2018;131:2047\u201359.","journal-title":"Blood"},{"key":"463_CR53","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","volume":"4","author":"D Chiron","year":"2014","unstructured":"Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2014;4:1022\u201335.","journal-title":"Cancer Discov."},{"key":"463_CR54","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","volume":"127","author":"P Martin","year":"2016","unstructured":"Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127:1559\u201363.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0463-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0463-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0463-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:37:26Z","timestamp":1684618646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0463-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["463"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0463-3","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,2]]},"assertion":[{"value":"26 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SLG is a consultant\/advisory board member and has received an honorarium from Roche and Janssen-Cilag. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}